Benzene-1,3,5-tricarboxamide Derived Ester Lipids and Uses Thereof
T2018-132 Ester lipid compounds, compositions, lipid-like nanoparticles, and methods for delivery of therapeutic, diagnostic, or prophylactic agent.
Over the last several years, messenger RNA (mRNA)-based treatments have been thoroughly evaluated as a potential therapeutic avenue in various fields for biomedical applications. However, the efficient delivery of mRNA remains a key challenge in mRNA-based therapy due to its instability and insufficient translatability thereby limiting the therapeutic potential. Although several clinical trials have reported promising data, there remains a great need to improve upon the current technology. Therefore, novel formulations of nanomaterials are needed to improve mRNA delivery to relevant tissues and enhance the actions of these compounds.
Researchers from The Ohio State University, led by Dr. Yizhou Dong, have created an extensive library of nanomaterials for mRNA based therapeutic applications. This library was created by conjugating benzene-1,3,5-tricarboxamide with diverse lipid derivatives to enhance mRNA delivery efficiency. In pre-clinical models Dr. Dong and colleagues have shown that several of these nanomaterials provide high delivery efficiency of mRNA to target cells. The creation of this extensive lipid-based nanoparticle library has the potential to greatly improve mRNA-based therapeutic applications.
- mRNA based therapeutics
- Preventative medicine (i.e. vaccines)
- Wide-ranging biomedical therapies
- Improved mRNA delivery efficiency
- Tunable biodegradability